TMS devices are used as a portable, non-invasive for the treatment of migraine headache.
In May 2014, eNeura received US Food and Drug Administration 510(k) clearance for its SpringTMS migraine treatment device.
SpringTMS is the first medical device available to patients in the United States for the acute treatment of pain associated with migraine headache with aura.
In consideration for the option to acquire eNeura, Orthofix has agreed to provide a USD 15m collateralised loan to support commercialization of SpringTMS in the United States and Europe.
If the option to purchase eNeura is exercised, Orthofix will pay USD 65m to consummate the merger and eNeura will repay to Orthofix the unpaid principal payable under the loan. In addition, Orthofix may make future milestone and royalty payments to eNeura.
Wells Fargo Securities served as financial advisor to eNeura.
Orthofix International N.V. is a diversified, global medical device company headquartered in Lewisville, TX. The company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia